{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    20,
    25,
    26,
    34,
    41,
    45,
    47,
    48,
    49,
    50,
    52,
    54
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Screening Site Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8",
        "sectionTitle": "Study Assessments and Procedures",
        "description": "Reference from a footnote in the Schedule of Activities (SoA) to Section 8, detailing procedures specific to screening-only sites in the US."
      },
      {
        "id": "ref_2",
        "name": "COVID-19 Vaccine Risk Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.5",
        "sectionTitle": "COVID-19 Vaccine Risk Assessment",
        "description": "Reference from the Coronavirus Disease 2019 section to the detailed COVID-19 vaccine risk assessment."
      },
      {
        "id": "ref_3",
        "name": "Dose Modification for Adverse Events",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "6.6",
        "sectionTitle": "Dose Modification",
        "description": "Reference from the Potential Risks and Mitigation Strategy table to the dose modification section for managing adverse events."
      },
      {
        "id": "ref_4",
        "name": "Adaptive Design Features Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 4",
        "sectionTitle": "Adaptive Protocol Features",
        "description": "Reference to Table 4, which describes the adaptive features of the study design."
      },
      {
        "id": "ref_5",
        "name": "Dose Modification Criteria Table",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 7",
        "sectionTitle": "ALXN1840 Dose Modifications for Individual Participants",
        "description": "Reference to Table 7, which outlines the criteria for decreasing or interrupting the study dose."
      },
      {
        "id": "ref_6",
        "name": "Blood Donation Exclusion Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.2",
        "sectionTitle": "Exclusion Criteria",
        "description": "Reference from Lifestyle Considerations to the exclusion criteria regarding blood donation prior to screening."
      },
      {
        "id": "ref_7",
        "name": "Contraception Guidance Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Contraceptive Guidance and Collection of Pregnancy Information",
        "description": "Reference from Lifestyle Considerations to the detailed section on appropriate contraceptive methods."
      },
      {
        "id": "ref_8",
        "name": "Contraception Inclusion Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "5.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference from Lifestyle Considerations to the inclusion criteria for contraception start times."
      },
      {
        "id": "ref_9",
        "name": "Discontinuation Procedures in SoA",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to the Schedule of Activities for data collection procedures at the time of study intervention discontinuation or participant withdrawal."
      },
      {
        "id": "ref_10",
        "name": "Pregnancy Discontinuation Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.2.6",
        "sectionTitle": "Pregnancy",
        "description": "Reference to the pregnancy section for guidance on discontinuing study intervention due to pregnancy."
      },
      {
        "id": "ref_11",
        "name": "ECG Schedule in SoA",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.3",
        "sectionTitle": "Schedule of Activities (SoA)",
        "description": "Reference to the Schedule of Activities for the schedule of 12-lead ECGs."
      },
      {
        "id": "ref_12",
        "name": "QTc Withdrawal Criteria Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL",
        "description": "Reference to the discontinuation section for QTc withdrawal criteria."
      },
      {
        "id": "ref_13",
        "name": "Clinical Laboratory Tests List",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to the section listing the clinical laboratory tests to be performed."
      },
      {
        "id": "ref_14",
        "name": "AE/SAE Procedures Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow-up, and Reporting",
        "description": "Reference to the section outlining procedures for detecting, documenting, and following up on AEs and SAEs."
      },
      {
        "id": "ref_15",
        "name": "Lost to Follow-up Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.3",
        "sectionTitle": "Lost to Follow-up",
        "description": "Reference to the definition of 'lost to follow-up' in the context of SAE follow-up."
      },
      {
        "id": "ref_16",
        "name": "Genetic Testing Clarification",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.7",
        "sectionTitle": "Genetics",
        "description": "Reference from the biobanked sample section to the genetics section, clarifying that samples will not be used for genetic testing."
      },
      {
        "id": "ref_17",
        "name": "PK/PD Sample Collection Schedule",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 1",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the Schedule of Activities table for the timing of pharmacokinetic and pharmacodynamic sample collection."
      },
      {
        "id": "ref_18",
        "name": "Copper/Molybdenum Measurement Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "8.1.1",
        "sectionTitle": "Copper and Molybdenum Balance Measurements",
        "description": "Reference to the section detailing the measurement of copper and molybdenum in food, drinks, urine, and feces."
      },
      {
        "id": "ref_19",
        "name": "Analysis Populations Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Table 8",
        "sectionTitle": "Populations for Analysis",
        "description": "Reference to the table defining the populations for statistical analyses."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Rationale for changing zinc washout period from 30 to 21 days: To align the number of days with the mention of zinc discontinuation elsewhere in the protocol.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "4.2 Scientific Rationale for Study Design",
        "pageNumber": 3
      },
      {
        "id": "annot_2",
        "text": "Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; IB = Investigatorâ€™s Brochure; PK = pharmacokinetics; WD = Wilson disease.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 3: Potential Risks and Mitigation Strategy",
        "pageNumber": 21
      },
      {
        "id": "annot_3",
        "text": "Adaptive Feature: The Outpatient Period (Day 9 to Day 23) may be extended up to an additional 14 days with Investigator approval.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 4. Adaptive Protocol Features",
        "pageNumber": 27
      },
      {
        "id": "annot_4",
        "text": "Abbreviations: CRF = case report form; CRU = clinical research unit; EOS = End of Study; SoA = Schedule of Activities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 5: Participant Lifestyle Considerations",
        "pageNumber": 35
      },
      {
        "id": "annot_5",
        "text": "Abbreviations: ICF = informed consent form; PD = pharmacodynamic; PK = pharmacokinetic.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Table 8: Populations for Analysis",
        "pageNumber": 51
      },
      {
        "id": "annot_6",
        "text": "Note on Accumulation Ratio calculation: total molybdenum and PUF molybdenum concentration-time profiles on Day 28 after the last 15 mg ALXN1840 dose will be extrapolated to Day 29 (0-24 hr) and subtracted from the observed Day 29 concentration-time profiles after the first 30 mg dose.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "9.4.4 Pharmacokinetic, Pharmacodynamic, and Biomarker Analyses",
        "pageNumber": 53
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "3.1 (US)",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2022-03-18",
        "description": "Clarify study procedures across US sites to facilitate participant recruitment and lessen inconvenience for participants.",
        "amendmentNumber": "Amendment 3.1 (US)"
      },
      {
        "id": "ver_2",
        "versionNumber": "3",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-08-31",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 3"
      },
      {
        "id": "ver_3",
        "versionNumber": "2",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2021-03-19",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 2"
      },
      {
        "id": "ver_4",
        "versionNumber": "1",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-08-18",
        "description": "Previous protocol version.",
        "amendmentNumber": "Amendment 1"
      },
      {
        "id": "ver_5",
        "versionNumber": "Original",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2020-05-12",
        "description": "Original approved protocol.",
        "amendmentNumber": "Original Protocol"
      }
    ],
    "summary": {
      "referenceCount": 19,
      "annotationCount": 6,
      "versionCount": 5
    }
  }
}